Company Profile

Reunion Neuroscience Inc. is engaged in the psychedelic drug development company that provides therapeutic solutions for mental health conditions by developing serotonin receptor agonist compounds. The Company is developing the advancement of synthetic molecules targeting serotonin 5HT2A receptors. The Company's products include RE104 and RE200. The Company's lead asset, RE-104, which is a psychedelic drug being developed for post-partum and treatment resistant depression as a potential fast-acting antidepressant with durable efficacy. The RE104 as a potentially fast-acting treatment for the key indications of postpartum and treatment resistant depression. The Company is developing the RE200 series, which includes compounds with potential for more selective serotonin receptor activity with reduced psych activity for potential use in more chronic treatment paradigms and indications. The Company is focused on the research and development of its RE200 molecule group.

Employees

Sector

Pharmaceuticals

More about the company

06-15	Reunion Neuroscience, Inc. Announces CEO Changes, Effective June 15, 2026	CI
06-15	Reunion Neuroscience, Inc. Announces Board and Executive Changes, Effective June 15, 2026	CI
02-23	U.S. FDA Grants Reunion Neuroscience's Luvesilocin Breakthrough Therapy Designation Status	CI
01-20	Reunion Neuroscience, Inc. Presents Full Data from RECONNECT Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression at ACNP Annual Meeting	CI
25-09-30	Reunion Neuroscience, Inc. Announces First Patient Dosed in REKINDLE Phase 2 Clinical Trial of RE104 for the Treatment of Adjustment Disorder in Cancer and Other Medical Illness	CI
25-09-16	Reunion Neuroscience Inc. announced that it has received $133 million in funding from a group of investors	CI
25-09-16	Reunion Neuroscience, Inc. Plans to Advance RE104 into Clinical Development for the Treatment of Generalized Anxiety Disorder	CI
25-08-18	Reunion Neuroscience, Inc. Announces Positive Topline Results from RECONNECT Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression	CI
25-07-22	Reunion Neuroscience Announces Publication of RE104 Phase 1 Data in The Journal of Clinical Psychopharmacology	CI
25-05-19	Reunion Neuroscience, Inc. Announces Last Patient Dosed in RECONNECT Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression	CI
24-10-09	Reunion Neuroscience Partners with Seleni Institute on Effective Diagnosis and Treatment of Maternal Mental Health Disorders	CI
24-07-23	Reunion Neuroscience Inc. Announces First Patient Dosed in Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression	CI
24-05-20	Reunion Neuroscience Announces Publication of Results from Early Preclinical Studies Demonstrating the Potential of Re104 for Development in Depressive Disorders	CI

23-05-01	ThinkEquity Initiates Reunion Neuroscience at Buy With $5 Price Target	MT
23-05-01	ThinkEquity Starts Reunion Neuroscience at Buy With $5 Price Target	MT
23-03-15	Reunion Neuroscience Downgraded to Hold at Stifel GMP as it Sues a Competitor; Price Target Cut to C$1.00	MT
22-12-16	EF Hutton Initiates Coverage on Reunion Neuroscience at Buy With $11 Price Target	MT
22-11-15	Reunion Neuroscience Kept at Speculative Buy at Stifel GMP After FQ2 Report; Price Target Cut 63% to C$5.00	MT

23-08-01	Reunion Neuroscience Inc. and MPM BioImpact Announce Completion of Plan of Arrangement	AQ
23-07-17	REUNION NEUROSCIENCE OBTAINS FINAL COURT ORDER FOR PROPOSED PLAN OF ARRANGEMENT	AQ
23-07-14	Reunion Neuroscience Inc. Obtains Final Court Order for Proposed Plan of Arrangement	AQ
23-07-13	Reunion Neuroscience Inc. Shareholders Approve Proposed Plan of Arrangement	AQ
23-07-07	Reunion Neuroscience : Annual Information Form For the Fiscal Year Ended March 31, 2023 - Form 6-K	PU

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
REUNION NEUROSCIENCE	-2.74%	-2.74%	-	-	12.46M
ELI LILLY AND COMPANY	-2.24%	-0.64%	+50.81%	+163.13%	1,085B
JOHNSON & JOHNSON	-0.29%	-0.35%	+63.88%	+62.01%	624B
ABBVIE INC.	-1.07%	-3.16%	+26.52%	+83.45%	442B
ROCHE HOLDING AG	+0.15%	-1.20%	+27.95%	+26.86%	332B
ASTRAZENECA PLC	-4.13%	-10.92%	+21.19%	+26.50%	277B
NOVARTIS AG	+0.14%	-2.60%	+25.59%	+45.26%	282B
NOVO NORDISK A/S	+0.36%	-1.56%	-29.36%	-39.39%	217B
AMGEN INC.	+0.01%	-0.90%	+20.89%	+61.59%	196B
GILEAD SCIENCES, INC.	-2.13%	+1.94%	+15.35%	+74.56%	167B
Average	-1.22%	-1.86%	+24.76%	+56.00%	402.44B
Weighted average by Cap.	-1.24%	-1.06%	+35.72%	+82.17%

Reunion Neuroscience Stock

Stocks

FTRP

CA76134G1037

Pharmaceuticals

Latest news : Reunion Neuroscience

Analysts' recommendations: Reunion Neuroscience

Press Releases: Reunion Neuroscience

Quotes and Performance

Other Pharmaceuticals

Company Profile